An Open Label Phase I Study of Brentuximab Vedotin Plus TAK228 for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Trial Profile

An Open Label Phase I Study of Brentuximab Vedotin Plus TAK228 for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Sapanisertib (Primary)
  • Indications Anaplastic large cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Sep 2017 Planned End Date changed from 1 Aug 2020 to 1 Dec 2020.
    • 07 Sep 2017 Planned primary completion date changed from 1 Aug 2020 to 1 Dec 2020.
    • 07 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top